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Abstract
Background: It is estimated that Lao People’s Democratic Republic (Lao PDR) ranks fifth among the seven
countries most affected by TB in the WHO Western Pacific Region. However, because of late implementation of
mycobacterial culture, no study on resistance to anti-TB drugs had been performed yet. The objective of this study
was to document drug resistance rate among patients hospitalized for pulmonary TB in threeprovinces of Lao PDR.
Methods: A cross-sectional study was conducted in three sites, one central and two regional hospitals, from April
to November 2010. For each TB suspected patient sputum smear microscopy and culture on Lowenstein-Jensen
media were performed. GenoType® MTBDRplus assay was used to test the susceptibility to isoniazid (INH) and
rifampicin (RMP), GenoType® MTBDRsl for second-line drugs and GenoType® Mycobacterium CMAS for non-
tuberculous mycobacteria (NTM).
Results: Out of 104 positive culture on Lowenstein-Jensen, 87 (83.6%) were M. tuberculosis and 17 (16.4%) were
NTM. Of 73 new TB cases, 5 isolates (6.8%) were resistant to INH. Of 14 previously treated cases, 2 isolates (14.3%)
were resistant to INH and one isolate was XDR.
Conclusion: Despite an overall rate of resistance still moderate, the frequency of mutations conferring INH
monoresistance and identification of the first strain of XDR require strengthening surveillance of drug resistant
tuberculosis in Lao PDR.
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Background
The control of tuberculosis (TB) in developing countries
is hampered by the progression of drug-resistant TB, espe-
cially multi-drug resistance (MDR). MDR-TB strains are
resistant to at least the first-line drugs isoniazid (INH) and
rifampicin (RMP), which significantly reduces the thera-
peutic arsenal. The weighted rates of resistance in the
world population are estimated among new cases at 17%
for any resistance and 2.9% for MDR, and among previ-
ously treated cases at 35% for any resistance and 15.3% for
MDR [1]. The World Health Organization (WHO) esti-
mates that each year 440,000 new cases of MDR-TB are
emerging globally, and 150,000 patients with MDR-TB
die. More worrying is the emergence of extensively drug-
resistant TB (XDR-TB) caused by MDR strains that also
resist to fluoroquinolones and second-line anti-TB inject-
able drugs (amikacin, kanamycin or capreomycin). WHO
estimates that 25,000 cases of XDR-TB emerge each year
worldwide. Unfortunately, only a small fraction of patients
infected by MDR or XDR-TB can access a screening by
culture, drug-susceptibility testing and appropriate man-
agement [2]. The use of new rapid molecular tests for
first-line drug resistance can dramatically reduce the de-
lays to detect MDR-TB and adapt the treatment. The good
performances of molecular line probe assays have led
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WHO to approve their use for rapid screening of patient
at risk of MDR-TB [3].
In Lao PDR, the burden of TB remains high: it is the
seventh leading cause of death in adults. In 2009, the
prevalence of all forms of TB was estimated at 289/100
000, the incidence at 151/100 000 and the mortality at 24/
100 000 [4]. The DOTS was implemented in 1995 by the
National Tuberculosis Control Program (NTCP) [5]. The
recommended treatment uses combinations of 5 drugs at
fixed doses (S: streptomycin, R: rifampicin, H: isoniazid, Z:
pyrazinamide, E: Ethambutol) corresponding to the fol-
lowing protocols: 2RHZE/6HE for new TB cases, 2RHZE/
4RH for TB-HIV co-infections and 2RHZES/6RHZE for
re-treatment. The therapeutic success rate of new smear
positive cases exceeds 90% since 2005 and reached 93% in
2009. However, a retrospective cohort study of TB pa-
tients showed that the 85% survival rate was lower than
the expected 91% from official statistics and that follow-
up should be strengthened to improve patient compliance
and allow contact tracing and detection of new cases [4,6].
The implementation of the first mycobacterial cultures in
2009 has made feasible the anti-TB drug susceptibility
testing [7]. The creation of a national reference laboratory
for TB allowed the realization of a first national preva-
lence survey in 2010–2011. But more efforts should be
implemented to achieve the Millennium Development
Goal 6 of halving TB prevalence and reverse its incidence
by 2015 [8].
In this context, this study aimed to provide a prelimin-
ary assessment of the rate of M. tuberculosis resistance
to isoniazid (INH), rifampicin (RMP) and second-line
drugs in Lao PDR using a molecular line probe assay.
Methods
Design of the study
We conducted a cross-sectional study from April to
November 2010 in a central hospital in Vientiane (Mahosot
hospital) and two provincial hospitals (Thakhek and Luang
Prabang). Patients enrolled in this study were directly ad-
mitted to one of the 3 hospitals and not transferred from
another health care facility.
Study population
All patients over 15 years attending the pneumology units
with symptoms suggestive of TB were included, regardless
of their HIV status, as well as patients given a TB treat-
ment. These patients were considered (i) as new cases if
never previously treated or beginning the treatment within
the last month prior inclusion, (ii) as previously treated
cases if the treatment started more than one month before
the inclusion [2]. Inclusion criteria were cough for over
two weeks, or bloody sputum, or suggestive radiological
signs, irrespective to HIV infection. Chest radiography or
tuberculin skin tests were not systematically performed.
Specimen processing
Two sputum samples were collected for each patient,
the first during the consultation, the second the next
morning upon awakening. Screening for acid-fast bacilli
(AFB) was locally performed in each hospital on Ziehl-
Neelsen stained smears. Sputum were then stored at 4°C
and sent to Rodolphe Mérieux Laboratory in Vientiane
once a week for culture and drug susceptibility testing.
Specimens were digested and decontaminated by the
N-acetyl-L-cystein-sodium hydroxide (NALC-NaOH) pro-
cedure [9], then inoculated on two slants of Lowenstein-
Jensen medium incubated at 37°C. Cultures were examined
once a week for 80 days. Any suspect colony confirmed as
AFB by microscopy was identified and tested for antibiotic
resistance.
Identification of M. tuberculosis and drug susceptibility
testing
When several cultures were positive for the same pa-
tient, only one was tested to detect drug resistances.
The GenoType® MTBDRplus (Hain lifescience Gmbh,
Germany) was used for M. tuberculosis complex identi-
fication and INH and/or RMP resistance detection
according to manufacturer's instructions.
In case of resistance to INH and/or RMP, the Genotype®
MTBDRsl (Hain lifescience Gmbh, Germany) was then
performed to detect the resistances to second-line
antibiotics.
Isolates not belonging to the M. tuberculosis complex
were identified using the Genotype® Mycobacterium CM/
AS (Hain lifescience Gmbh, Germany) that can differenti-
ate 13 species of clinically relevant non-tuberculous myco-
bacteria (NTM).
Statistical analysis
Data were entered with EPI data 3.1 and analyzed with
Stata 8.0. The chi2 test was used to compare qualitative
variables with a significance level of 0.05.
Ethical clearance
This study was approved by the National Ethics Com-
mittee of Lao PDR and the National Tuberculosis Con-
trol Program Center (# 201/NECHR).
A written informed consent for participation in the
study was obtained from participants. Only patients over
15 years old with signed informed consent were included
in the study.
Results
Mycobacterial culture and identification
Eighty-seven isolates (83.6%) were identified as belong-
ing to the M. tuberculosis complex, evenly distributed
between the three sites (p=0.1). The 17 remaining strains
(16.4%) were NTM of which 10 were identified as
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M. fortuitum (8), M. scrofulaceum (1) and M. abscessus
(1). Out of the 87M. tuberculosis strains, 74 were iso-
lated from new cases while 13 were isolated from previ-
ously treated cases (Table 1).
Characteristics of patients
Among the 87 patients with at least one positive culture
for M. tuberculosis, 34 (39.1%) lived in Vientiane, 31
(35.6%) in Thakhek and 22 (25.3%) in Luang Prabang.
Sex ratio (M/F) was 1.3 and mean age 48 years. Most of
the patients were new cases (85%). The 13(15%) patients
previously treated or treated for more than 1 month
were unevenly distributed among the three sites: 63%
Vientiane, 19% in Luang Prabang and 19% in Thakhek.
HIV status was only known for 5 patients; none of
whom were HIV positive (Table 2).
Drug resistance
Resistance to first line drugs
Among the 87M. tuberculosis isolates, 8 (9.2%) were
found resistant: 7 mono-resistant to INH and 1 to both
INH and RMP; 3 (13.6%) in Luang Prabang, 3 (9.7%) in
Thakhek and 2 (5.9%) in Vientiane, without significant
difference between the three sites (p=0.5). Five of them
were isolated from new cases and were resistant to INH:
two mutated in the katG gene (S315T), two in the inhA
gene (C15T) and one in both genes katG (S315T) and
inhA (C15T) (Table 3). The three remaining isolates
were from previously treated cases: they were resistant
to INH by S315T mutation in katG or by deletion of this
gene. For this last strain (165 LP), none of the 4 katG
locus probes on the strip reacted; further sequencing
showed neither katG gene nor katG promoter could be
amplified using several inner and outer primers, reflecting
the complete deletion of this gene. To further analyze this
strain, rpoB, pncA, inhA and ahpC genes were sequenced.
No mutation was observed in rpoB, pncA and inhA genes,
suggesting RMP and pyrazinamide susceptibility. The
ahpC gene sequencing revealed the ambiguous base calls
in the −51, -52 and −57 promoter positions. Therefore,
amplicons were cloned and 20 of them were sequenced.
Interestingly, the results showed the coexistence of three
different mutational profiles, none with more than one
mutated site. This strain was isolated from an 82-old pa-
tient who had received a TB treatment six years ago and
was considered cured. He relapsed in 2012 and died
quickly, before the culture results are positive. The third
strain (175 TK) was also resistant to RMP by mutation in
the rpoB gene (H526Y) and was therefore MDR (Table 3).
Drug resistance
Resistance to second-line drugs
Out of the five new cases displaying resistance muta-
tions, two INH-resistant strains were also resistant to
aminoglycosides and cyclic peptides showing a C1402T
mutation on the rrs gene. Out of the three previously
treated cases, two strains were resistant to at least one
second-line drug (Table 3).
The MDR-TB isolate (175-TK) displayed three further
mutations: M306V in embB gene, A90V in gyrA gene
and C1402T in rrs gene. This strain was sent to Korean
Institute of Tuberculosis (KIT, Seoul, Korea) to perform
a conventional antibiogram with the second line drugs.
It turned out that this strain was indeed resistant to
RMP, INH, ethambutol, fluoroquinolones, streptomycin
and aminoglycosides/cyclic peptides, and it was there-
fore an XDR strain. The patient (175 TK) was a 31 years
old woman, diagnosed pulmonary TB in 2004 and
treated with a first line regimen (2RHZE/6HE) for
8 months. She was considered clinically cured with
smear microscopy negative at fifth month of treatment.
She relapsed in 2007 and received a second-line treat-
ment (2RHZES/6RHZE) for 8 months followed by INH
monotherapy for 3 years. In 2010, the diagnosis of
chronic pulmonary TB resistant to treatment was bac-
teriologically confirmed. She then received a combin-
ation therapy of HZE, kanamycin and ofloxacin for
6 months (Table 4).
Discussion
The recent implementation of mycobacterial culture in
Laos PDR had made possible the necessary monitoring
of resistance to anti-TB drugs. This multicenter study
aimed to provide preliminary data on the rate of re-
sistance to first-line anti-TB, especially INH and RMP.
Patient enrolled were outpatients, not referred from per-
ipheral clinics, thus not being at higher risk of drug re-
sistant. The results show an overall rate of resistance of
approximately 10%, homogeneously distributed among
the 3 sites. It reached 6.8% among new cases and 21.4%
among previously treated cases. Despite a sampling not
as robust as national survey, this study shows similar
Table 1 Results of culture and identification
Number of patients with Total Vientiane Thakhek Luang Prabang p
≥ 1 positive culture (%) 104 39 (37.5) 38 (36.5) 27 (26)
M. tuberculosis complex 87 34 (39.1) 31 (35.6) 22 (25.3) 0.7
NTM* 17 5 (29.4) 7 (41.2) 5 (29.4)
*NTM non-tuberculous mycobacteria (8M. fortuitum, 1M. scrofulaceum, 1M. abscessus and 7 unidentified).
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rates compared to neighboring countries: Cambodia, 10%
and 16.6% in the 2001–2002 national survey [10], and
Myanmar, 10% and 30.2% in the 2002 national survey [11].
However, it remains well below the rates reported in
Thailand, 20.9% and 53.6% in 1996 [12], in Vietnam, 26.3%
and 62.9% in 2001 [13] and in China, 27.9% and 60.3% in a
meta-analysis covering the period 1993–2011 [14].
All the resistant isolates of this study showed mu-
tations conferring resistance to INH. The only isolate
resistant to RMP, also carrying mutations conferring re-
sistance to second-line antibiotics, came out to be an
XDR. Even though no strictly MDR strain was isolated
during the study, these results show the existence of
resistance mutations in TB isolates that may lead to
compromise the effectiveness of treatment regimens
recommended by the NTCP.
This study presents a number of limitations. The pa-
tient sampling was performed in three large hospitals
which do not represent the whole country. A recruit-
ment in remote district hospitals where patient follow-
up and compliance to DOTS are less easy to perform [6]
might have revealed higher levels of resistance. The HIV
status of patients was unknown for 92% of patients, indi-
cating that the recommendations for routine screening
of HIV-TB co-infection had not been yet systematically
applied. The exclusive use of a molecular test for rapid
Table 2 Characteristics of patients
Total Mahosot Thakhek Luang Prabang
p
87 34 (39%) 31 (36%) 22 (25%)
Gender
0.8Male 50 21 (42) 17 (34) 12 (24)
Female 37 13 (35.2) 14 (37.8) 10 (27)
Average age (IC95%) 48 (45-52) 52 (45-59) 46 (41-51) 46 (38-55)
Age groups
0.06
• ≥15-25< years 7 3 (42.9) 1 (14.2) 3 (42.9)
• ≥25-55≤ years 48 14 (29.2) 23 (47.9) 11 (22.9)
• > 55 years 32 17 (53.2) 7 (21.9) 8 (25)
TB history
<0.4Never treated or <1 months 74 27 (36.5) 28 (37.8) 19 (25.7)
Previously treated or ≥ 1 months 13 7 (53.8) 3 (23.1) 3 (23.1
HIV status
0.1
Positive 0 - - -
Negative 5 1 (20) 4 (80) 0 (0)
Unknown 82 33 (40.3) 27 (32.9) 22 (26.8)







Mutations conferring resistance to






472 (TK) No inhA C15T - - - -
977 (MV) No katG S315T - - - -
454 (MV) Yes katG S315T - - - -
446 (LP) No inhA C15T - - rrs C1402T -
480 (TK) No katG S315T - - rrs C1402T -
165 (LP) Yes katG deleted - - rrs C1402T -
175 (TK) Yes katG S315T rpoB H526Y gyrA A90V rrs C1402T embB M306V
Total 8 1 1 4 1
LP Luang Prabang, MV Mahosot Vientiane, TK Thakhek, INH isionazid, RMP rifampycin, FLQ fluoroquinolones, AG/CP aminoglycosides, cyclic peptides,
EMB ethambutol.
(−) Presence of all wild type probes and none mutation probe observed.
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species identification of mycobacterial isolates and for
detection of antibiotic resistance may also lead to under-
estimate INH resistance. This line probe assay is part of
rapid methods recommended by WHO for detection of
MDR strains as a substitute for conventional methods
which require 4 to 6 weeks. It can even be performed
directly from sputum samples found positive at micros-
copy. Rapid detection of resistance to RMP is a major
issue because it can be considered a surrogate marker
for MDR strains [15]. According to a meta-analysis of 14
comparative studies for RMP and 15 for INH, perfor-
mances of the GenoType MTBDR assay are considered
satisfactory, except for the detection of INH resistance
whose sensitivity approaches 90% with the MTBDRplus
assay [16]. Some strains phenotypically resistant to INH
are found genetically susceptible, possibly because of
mutations involving genes other than inhA and katG
[17]. Similarly, the MTBDRsl assay showed an excellent
specificity in detecting resistance to second-line drugs,
but a variable sensitivity, especially for the detection of
resistance to fluoroquinolones and ethambutol [18,19].
The inclusion of new alleles is recommended in order to
reduce the proportion of false negative results [20].
The eight resistant strains isolated in our study all
showed a mutation conferring resistance to INH: 5 in
katG, 2 in inhA and the remaining 1 in both katG and
inhA. Interestingly, the three inhA promoter mutants
were observed in new cases,. A study conducted during
a 9-years period in San Francisco showed that strains
with a katG S315T or inhA promoter mutation were
more likely to spread than otherwise mutated strains
[21]. However, mutations in the inhA promoter are more
common among INH-monoresistant isolates than among
MDR isolates [22]. It is in all cases a C15T mutation which
is associated with a low level of resistance [23]. This mu-
tation confers co-resistance to INH and ethionamide [24].
Of the 6 strains mutated in katG, 5 had the S315T
mutation, currently considered as a risk factor for fur-
ther development of MDR-TB [25]. The last one had a
complete deletion of this gene, a mechanism rarely
found associated with clinical INH-resistance [26,27]. By
sequencing, the distinction of three clones each carrying
one peculiar mutation in the ahpC gene is consistent
with the hypothesis that up regulation mutations in the
ahpC promoter compensate for the loss of catalase-
peroxidase activity encoded by the katG gene [28].
The only case of RMP-resistance was due to a muta-
tion H526Y in the rpoB gene. With codons 531 and 516,
this point mutation is one of the most frequently associ-
ated with resistance to RMP [29].
Four strains, two from new cases and two from previ-
ously treated cases, exhibited a C1402T mutation in the rrs
gene, presumed to confer resistance to aminoglycosides
and cyclic peptides: this mutation was found associated
with high levels of resistance to capreomycin, but with low
levels of resistance to kanamycin and amikacin [30]. Re-
garding the two new cases, this mutation strongly suggests
a primary resistance whose origin is unclear, the only
aminoglycoside antibiotic widely used in Lao PDR as first-
line treatment until the 2000s being the streptomycin.
Despite the progress made by the NTCP to achieve
the WHO objectives, implementation of the DOTS strat-
egy in Lao PDR is limited by the remoteness of the tar-
get population to health centers, the difficult follow-up
of patients under TB treatment and the lack of compli-
ance. The recent development of mycobacterial culture
and the use of line probe assays have allowed identifying
the species of the M. tuberculosis complex and, for the
first time, to detect resistances to anti-TB drugs. This
preliminary investigation shows that resistance muta-
tions, especially against INH, are present among the new
cases, some of which may evolve towards MDR.
Table 4 History of the three previously treated patients
Patient number (hospital)
454 (MV) 165 (LP) 175 (TK)
Gender / age (years) M / 54 M / 82 F / 31
date of 1st diagnosis of TB 2003 2004 2004
1st anti-TB regimen 2RHZE/6HE 2RHZE/6HE 2RHZE/6HE
Outcome of 1st TB treatment recovery recovery failure
Date of TB relapse 2010 2012 2007
Date of initiation of treatment 2012 a 2007
Current anti-TB regimen 2RHZES a 2RHZES/6RHZE
Duration of treatment 2 months a 8 months + H 3 years
Compliance with TB treatment unknown a high
Clinical response to treatment poor a poor (b)
a: the patient died before the culture results and did not receive the second-line treatment.
b: chronic pulmonary tuberculosis resistant to treatment.
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The isolation of an XDR strain from a patient enrolled
in a provincial hospital is the result of chance. This
strain acquired resistance as a result of successive treat-
ments; XDR being the consequence of adding only 2
drugs never received to a previous treatment failure, in-
stead of 5 as recommended by WHO. In Cambodia, of
101 MDR strains isolated between 2007 and 2009, only
one was found XDR [31]. However, this must sound like
a threat because the XDR strains have the ability to
spread in the population by intra-community transmis-
sion [32] and justifies the strengthening and extension of
the laboratory network for tuberculosis in the different
provinces of Lao PDR. The use of line probe assays such
as MTBDR tests should now be recommended to rapidly
detect and treat without delay the MDR-TB cases.
Conclusion
The frequency of primary resistance to INH and identifi-
cation of the first XDR strain strongly justify to strengthen
and expand the screening of resistant TB in the provinces
of Lao PDR.
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